Crossmark

[Translated article] Alemtuzumab in relapsing–remitting multiple sclerosis in clinical practice: Annual NEDA-3 follow-up for up to 4 years

Crossref DOI link: https://doi.org/10.1016/j.farma.2025.12.005

Published Print: 2026-05

Update policy: https://doi.org/10.1016/elsevier_cm_policy

Authors

Herrero-Poch, Leticia

Fortes-González, Maria Susana

Pato-Pato, Antonio

Gaveiras-Araújo, Pablo

Lorenzo-García, Martín

García-Estévez, Daniel Apolinar

Lorenzo-González, Jose Ramón
License Information

Text and Data Mining valid from 2026-05-01

Text and Data Mining valid from 2026-05-01

Version of Record valid from 2025-12-17
More Information

This article is maintained by: Elsevier

Article Title: [Translated article] Alemtuzumab in relapsing–remitting multiple sclerosis in clinical practice: Annual NEDA-3 follow-up for up to 4 years

Journal Title: Farmacia Hospitalaria

CrossRef DOI link to publisher maintained version: https://doi.org/10.1016/j.farma.2025.12.005

CrossRef DOI link to the associated document: https://doi.org/10.1016/j.farma.2025.10.011

Content Type: article

Copyright: © 2025 Sociedad Española de Farmacia Hospitalaria (S.E.F.H). Published by Elsevier España, S.L.U.